Key result
Venous pressure therapy cuts lower-limb DVT risk by ~80% versus control.
Why the study?
The study was conducted to evaluate the biochemical and clinical significance of venous pressure therapy in preventing venous thromboembolism through analysis of coagulation and fibrinolysis biomarkers.
Does venous pressure therapy improve coagulation biomarkers and prevent lower-extremity deep venous thromboembolism?
Meta-Analysis
Does venous pressure therapy improve coagulation biomarkers and prevent lower-extremity deep venous thromboembolism?
Venous pressure therapy favorably alters coagulation and fibrinolytic biomarkers, correlating with a lower incidence of lower-extremity deep venous thrombosis.
Supports venous pressure therapy for VTE prevention; extends RCT evidence linking biomarker changes to reduced DVT incidence.
Background: To evaluate the biochemical and clinical significance of venous pressure therapy in preventing venous thromboembolism (VTE) through analysis of coagulation and fibrinolysis biomarkers, including fibrinogen (FIB), D-dimer (D-D), and activated partial thromboplastin time (APTT). Methods: Randomized controlled trials published between 2013 and 2025 were systematically retrieved from PubMed, CNKI, VIP, and Wanfang databases. Eligible studies investigated venous pressure therapy and reported coagulation-related indices. Pooled effect sizes were calculated for key biochemical markers (FIB, D-D, APTT, PT, TT) and venous hemodynamic outcomes. Results: Nineteen clinical studies met inclusion criteria. Meta-analysis revealed that venous pressure therapy significantly reduced plasma FIB and D-D levels, prolonged APTT, prothrombin time (PT), and thrombin time (TT), and improved venous blood flow velocity. These changes reflect improved anticoagulant activity, enhanced fibrinolysis, and reduced risk of thrombosis. Importantly, the observed modulation of biochemical markers correlated with a lower incidence of lower-extremity deep venous thrombosis. Conclusions: Venous pressure therapy favorably alters coagulation and fibrinolytic biomarkers, underscoring their diagnostic value in monitoring therapeutic efficacy and thrombotic risk. These findings highlight the critical role of laboratory indices in guiding the prevention and management of VTE, supporting their integration into standardized clinical practice.
No takes yet. Share an insight, caveat, or question.
Niu et al. (2025) conducted a meta-analysis in Lower-extremity deep venous thromboembolism (VTE/DVT). Venous pressure therapy vs. Control group was evaluated on Incidence of lower-limb deep vein thrombosis (RR 0.20, 95% CI 0.14-0.29, p=<0.00001). Venous pressure therapy significantly reduced the incidence of lower-limb deep vein thrombosis compared to the control group (RR 0.20).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: